Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
40 mg telmisartan
5 mg amlodipine
5 mg amlodipine
80 mg telmisartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion criteria:
Essential hypertensive patients
- If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg
- If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg
- Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.
Exclusion criteria:
- Patients taking 3 or more antihypertensive drugs at signing the informed consent form
- Patients with known or suspected secondary hypertension
- Patients with clinically relevant cardiac arrhythmia
- Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
- Patients with recent cardiovascular events
- Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form
- Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
- Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
- Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs
- Patients with hepatic and/or renal dysfunction
- Pre-menopausal women who are nursing or pregnant
Sites / Locations
- 1235.37.01 Boehringer Ingelheim Investigational Site
- 1235.37.07 Boehringer Ingelheim Investigational Site
- 1235.37.08 Boehringer Ingelheim Investigational Site
- 1235.37.02 Boehringer Ingelheim Investigational Site
- 1235.37.05 Boehringer Ingelheim Investigational Site
- 1235.37.03 Boehringer Ingelheim Investigational Site
- 1235.37.06 Boehringer Ingelheim Investigational Site
- 1235.37.04 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
80mg telmisartan and 5mg amlodipine FDC
40mg telmisartan and 5mg amlodipine FDC
Arm Description
once daily
once daily
Outcomes
Primary Outcome Measures
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Secondary Outcome Measures
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Seated DBP Control Rate at Trough
DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Seated SBP Control Rate at Trough
SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Seated DBP Response Rate at Trough
DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (<90 mmHg and/or reduction from reference baseline >=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Seated SBP Response Rate at Trough
SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (<140 mmHg and/or reduction from reference baseline >=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Seated Blood Pressure (BP) Normalisation at Trough
Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01286558
Brief Title
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
Official Title
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug alone, often a combination of two or more drugs is essential to achieve a sufficient antihypertensive effect. Therefore in Japanese Society of Hypertension (JSH) 2009 combination therapy is recommended. In JSH 2009 it is advised to start the combination therapy at a low dose, and to increase the dosage when the antihypertensive effect is not sufficient. In the Japanese long-term safety study, 259 patients received the T40/A5 mg fixed-dose combination (FDC), and after 6 weeks treatment 48 patients of them could not control their blood pressure (DBP =90) (U09-2494-01). For those patients who cannot control their blood pressure with T40/A5 mg FDC, a switch to a higher dose such as T80/A5 mg is recommended.
In the overseas 4x4 factorial design trial, a clinically meaningful difference of the blood pressure lowering effect between T80/A5 mg free combination and T40/A5 mg free combination was shown (U07-3503-02). But the sponsor has no data that verifies this difference in Japanese patients.
Thus, this clinical trial is being conducted to investigate the antihypertensive effect and safety of high dose T80/A5 mg FDC compared with low dose T40/A5 mg FDC in Japanese patients with essential hypertension. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
225 (Actual)
8. Arms, Groups, and Interventions
Arm Title
80mg telmisartan and 5mg amlodipine FDC
Arm Type
Experimental
Arm Description
once daily
Arm Title
40mg telmisartan and 5mg amlodipine FDC
Arm Type
Active Comparator
Arm Description
once daily
Intervention Type
Drug
Intervention Name(s)
40 mg telmisartan
Intervention Description
once daily
Intervention Type
Drug
Intervention Name(s)
5 mg amlodipine
Intervention Description
once daily
Intervention Type
Drug
Intervention Name(s)
5 mg amlodipine
Intervention Description
once daily
Intervention Type
Drug
Intervention Name(s)
80 mg telmisartan
Intervention Description
once daily
Primary Outcome Measure Information:
Title
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Time Frame
Reference baseline, 8 weeks
Secondary Outcome Measure Information:
Title
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Time Frame
Reference baseline, 8 weeks
Title
Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Reference baseline, 8 weeks
Title
Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Reference baseline, 8 weeks
Title
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP
Description
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Pseudo-baseline, 14 weeks
Title
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Description
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Pseudo-baseline, 14 weeks
Title
Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Reference baseline, 8 weeks
Title
Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Description
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time Frame
Reference baseline, 8 weeks
Title
Seated DBP Control Rate at Trough
Description
DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Time Frame
8 weeks
Title
Seated SBP Control Rate at Trough
Description
SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Time Frame
8 weeks
Title
Seated DBP Response Rate at Trough
Description
DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (<90 mmHg and/or reduction from reference baseline >=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Time Frame
8 weeks
Title
Seated SBP Response Rate at Trough
Description
SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (<140 mmHg and/or reduction from reference baseline >=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Time Frame
8 weeks
Title
Seated Blood Pressure (BP) Normalisation at Trough
Description
Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Eligibility Criteria
Inclusion criteria:
Essential hypertensive patients
If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg
If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg
Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.
Exclusion criteria:
Patients taking 3 or more antihypertensive drugs at signing the informed consent form
Patients with known or suspected secondary hypertension
Patients with clinically relevant cardiac arrhythmia
Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
Patients with recent cardiovascular events
Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form
Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs
Patients with hepatic and/or renal dysfunction
Pre-menopausal women who are nursing or pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1235.37.01 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Tokyo
Country
Japan
Facility Name
1235.37.07 Boehringer Ingelheim Investigational Site
City
Hiroshima, Hiroshima
Country
Japan
Facility Name
1235.37.08 Boehringer Ingelheim Investigational Site
City
Itoshima, Fukuoka
Country
Japan
Facility Name
1235.37.02 Boehringer Ingelheim Investigational Site
City
Katsushika-ku, Tokyo
Country
Japan
Facility Name
1235.37.05 Boehringer Ingelheim Investigational Site
City
Osaka, Osaka
Country
Japan
Facility Name
1235.37.03 Boehringer Ingelheim Investigational Site
City
Ota-ku, Tokyo
Country
Japan
Facility Name
1235.37.06 Boehringer Ingelheim Investigational Site
City
Suita, Osaka
Country
Japan
Facility Name
1235.37.04 Boehringer Ingelheim Investigational Site
City
Yokohama, Kanagawa
Country
Japan
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.37_U11-2633-02.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.37_Literature.pdf
Description
Related Info
Learn more about this trial
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
We'll reach out to this number within 24 hrs